Australia's 4DMedical soars as US FDA clears lung diagnostic tool
** Shares of Australia's 4DMedical 4DX.AX rise as much as
14.7% to A$0.545, hitting their highest since early December
2024
** Medical technology-focussed firm says it has received
clearance from the U.S. Food and Drug Administration for its
IQ-UIP™ product
** The product is an advanced AI-driven lung diagnostic tool
designed for the diagnosis of usual interstitial pneumonia
** Stock fell 32.9% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Recent news on 4DMedical
See all newsBrief: 4Dmedical Receives TGA Approval For CTVQ In Australia
Brief: 4Dmedical Launches Clear Clinical Evidence Program
Brief: 4Dmedical Creates EU Platform Via Contextflow Acquisition
Australia's 4DMedical rises on establishing European platform via acquisition
Brief: 4Dmedical Says CT:VQ Enters US Outpatient Market Via Simonmed's 170-Site Network